Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 9.79
-0.27 (-2.68%)
Sep 10, 2026, 11:56 AM HKT
Ascletis Pharma Stock Forecast
Stock Price Forecast
According to 3 analysts polled by S&P Global, Ascletis Pharma stock has a consensus rating of "Buy" and an average price target of $22.46. The average 1-year stock price forecast is 129.42% higher than the current stock price, while the lowest is $13.88 (+41.78%) and the highest is $31.05 (+217.16%).
Price Target: $22.46 (+129.42%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ascletis Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 1 |
| Buy | 1 | 0 | 0 | 0 | 0 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Orient Securities No rating | Orient Securities | Buy Maintains $13.83 → $14.53 | Buy | Maintains | $13.83 → $14.53 | +48.42% | Sep 6, 2026 |
Linhai Percy Zhao, Ph.D. Goldman Sachs No rating | Goldman Sachs | Hold Maintains $15.71 → $13.86 | Hold | Maintains | $15.71 → $13.86 | +41.57% | Sep 2, 2026 |
Financial Forecast
Revenue This Year
2.00M
from 2.03M
Decreased by -1.38%
Revenue Next Year
69.01M
from 2.00M
Increased by 3,350.73%
EPS This Year
n/a
EPS Next Year
n/a
Financial currency is CNY.